Back to results
US 2023/0068129 A1Published application
Multispecific Antigen-Binding Molecules for Cell Targeting and Uses Thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLauric Haber, Jennifer A. Finney, Ryan McKay, Eric Smith, Chia-Yang Lin
Life of this patent
Estimating the term…
Abstract
The present invention provides multispecific antigen-binding molecules that bind both a T-cell antigen (e.g., CD3) and a target antigen (e.g., a tumor associated antigen, a viral or bacterial antigen), and which include a single polypeptide chain that is multivalent (e.g., bivalent) with respect to T-cell antigen binding, and uses thereof.
Claims25
1-93. (canceled)
A method of treating cancer, comprising administering to a subject in need thereof, a multispecific antigen-binding molecule, comprising:
- (a) a first polypeptide comprising, from N-terminus to C-terminus (i) a first antigen-binding domain that specifically binds a T cell antigen, (ii) a first multimerizing domain, and (iii) a second antigen-binding domain that specifically binds a T cell antigen;
- and
- (b) a second polypeptide comprising, from N-terminus to C-terminus (i) a third antigen-binding domain that specifically binds a target antigen, (ii) a second multimerizing domain, and (iii) a fourth antigen-binding domain that specifically binds a target antigen,
- wherein the first and the second multimerizing domains associate with one another to form the molecule, and wherein the first antigen-binding domain and the third antigen-binding domain are scFv domains and the second antigen-binding domain and the fourth antigen-binding domain are Fab domains.
1 more element
Dependencies are inferred from the claim text.